Related references
Note: Only part of the references are listed.Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
Massimo Gentile et al.
LEUKEMIA (2021)
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients
Fuli Fan et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
Jordan Gauthier et al.
BLOOD (2021)
Chronic lymphocytic leukemia prognostic models in real life: still a long way off
Stefano Molica
EXPERT REVIEW OF HEMATOLOGY (2021)
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
Elisavet Vlachonikola et al.
FRONTIERS IN IMMUNOLOGY (2021)
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
Mauricette Michallet et al.
BONE MARROW TRANSPLANTATION (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Maissa Mhibik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
Jim S. Qin et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
Manuela A. Hoechstetter et al.
LEUKEMIA (2020)
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
Victor S. Lin et al.
BLOOD (2020)
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
Adalgisa Condoluci et al.
BLOOD (2020)
Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation
M. Rovira et al.
BONE MARROW TRANSPLANTATION (2020)
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Anthony R. Mato et al.
CLINICAL CANCER RESEARCH (2020)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2020)
Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape
Lorenzo Iovino et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Wei Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Chronic lymphocytic leukemia in 2020: a surfeit of riches?
Sameer A. Parikh et al.
LEUKEMIA (2020)
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences
Candida Vitale et al.
FRONTIERS IN ONCOLOGY (2020)
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation
L. Farina et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Kathryn M. Cappell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf et al.
LANCET ONCOLOGY (2020)
Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect
Pavan Bachireddy et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab
Massimo Gentile et al.
BLOOD CANCER JOURNAL (2020)
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Lindsey E. Roeker et al.
BLOOD ADVANCES (2020)
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia
Haesook T. Kim et al.
BLOOD ADVANCES (2020)
Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients
Tanya Siddiqi et al.
BLOOD (2020)
Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
William G. Wierda et al.
BLOOD (2020)
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
Jennifer R. Brown et al.
BLOOD (2020)
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Anthony R. Mato et al.
BLOOD (2020)
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
Thomas E. Lew et al.
BLOOD ADVANCES (2020)
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Peter Dreger et al.
BONE MARROW TRANSPLANTATION (2019)
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease
Stephen Man et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
Jacob D. Soumerai et al.
LANCET HAEMATOLOGY (2019)
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Philip A. Thompson et al.
BLOOD (2019)
Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty
Emil Montserrat et al.
CANCER (2019)
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Yi-Xin Zou et al.
HEMATOLOGICAL ONCOLOGY (2019)
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning
Niels Smedegaard Andersen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Mazyar Shadman et al.
BLOOD ADVANCES (2019)
Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
Brian T. Hill et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
Peter Dreger et al.
BLOOD (2018)
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Inhye E. Ahn et al.
BLOOD (2018)
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien et al.
BLOOD (2018)
Is there expert consensus on expert consensus?
Giovanni Barosi et al.
BONE MARROW TRANSPLANTATION (2018)
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation
Shimrit Ringelstein-Harlev et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate
Saar I. Gill et al.
BLOOD (2018)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
T cells in chronic lymphocytic leukemia: can they fight?
Anna Vardi et al.
ONCOTARGET (2017)
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
Jeffrey A. Jones et al.
LANCET HAEMATOLOGY (2017)
Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
Michel van Gelder et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
Isabelle Kraemer et al.
BLOOD (2017)
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)
Johannes Schetelig et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
J. Schetelig et al.
BONE MARROW TRANSPLANTATION (2017)
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI
Julio Delgado et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Ibrutinib-A double-edge sword in cancer and autoimmune disorders
Parviz Kokhaei et al.
JOURNAL OF DRUG TARGETING (2016)
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
Christine E. Ryan et al.
BLOOD (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
Is there really a specific graft-versus-leukaemia effect?
R. P. Gale et al.
BONE MARROW TRANSPLANTATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Michael Hallek
LANCET ONCOLOGY (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
Jiazhu Wu et al.
ONCOTARGET (2016)
Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL
David L. Porter et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT
Peter Dreger et al.
BLOOD (2016)
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
M. Hahn et al.
BONE MARROW TRANSPLANTATION (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen-Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?
Mitchell Sabloff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Outcomes of Human Leukocyte Antigen-Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens
Ronald M. Sobecks et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
John C. Riches et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Increased risk of second malignancies inchronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study
S. Beiggi et al.
BRITISH JOURNAL OF CANCER (2013)
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia
Brian C. Shaffer et al.
EXPERIMENTAL HEMATOLOGY (2013)
Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
J. R. Brown et al.
LEUKEMIA (2013)
Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis
M. A. Kharfan-Dabaja et al.
BONE MARROW TRANSPLANTATION (2012)
Markov model of CLL transplants
R. P. Gale
BONE MARROW TRANSPLANTATION (2012)
Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting
Brian L. McClune et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Chronic lymphocytic leukemia and autoimmunity: a systematic review
Kate Hodgson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Renier Brentjens et al.
MOLECULAR THERAPY (2010)
T-cell function in chronic lymphocytic leukaemia
John C. Riches et al.
SEMINARS IN CANCER BIOLOGY (2010)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia:: results from the GCLLSG CLL3X trial
M. Ritgen et al.
LEUKEMIA (2008)
Genetically identical twin transplantation for chronic lymphocytic leukemia
S. Z. Pavletic et al.
LEUKEMIA (2007)
Graft-versus-leukemia in chronic lymphocytic leukemia
I. Ben-Bassat et al.
BONE MARROW TRANSPLANTATION (2007)
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
J Delgado et al.
BLOOD (2006)
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
M Beyer et al.
BLOOD (2005)
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia
ML Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis
P Dreger et al.
LEUKEMIA (2005)
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation:: The Cooperative German Transplant Study Group
J Schetelig et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
